US generics comprise ~30% of total revenues. So far, the company has received approval for 165 ANDAs while another 47 are pending approval, of which 24 are Para IV applications. However, Glenmark's derma portfolio is facing stiff pricing pressure in the US. Going ahead, traction from the newly commissioned US based Monroe facility will be the key determinant besides sustained product launches. We expect the US to grow at 4.7% CAGR in FY20-23E to | 3602 crore on the back of new launches. Targeting specific therapies in IPM...